Molecular monitoring of minimal residual disease (MRD) and BCR-ABL1 kinase domain
(KD) mutation testing have a well consolidated role in the routine management of chronic …

Tyrosine kinase inhibitors (TKIs) have drastically changed the outcome of chronic myeloid
leukemia (CML) patients. A sustained and deep molecular response achieved over time …

Abstract Treatment‐free remission (TFR) by tyrosine kinase inhibitors (TKI) discontinuation
in patients with deep molecular response (DMR) is a paramount goal in the current chronic …

Simple Summary The monitoring of the minimal residual disease (MRD) in Chronic Myeloid
Leukemia is a key element in the management of affected patients because it reflects the …

Due to the discovery of their role in intra‑cellular communications, exosomes, which carry
information specific to the cell of origin, have garnered considerable attention in cancer …

Ph+ chronic myeloid leukemia (CML) is a clonal myeloproliferative disease whose clinical
course is characterized by progression disease from the early chronic phase (CP) to the fatal …

Real-time quantitative PCR (RT-qPCR) is the gold standard to quantify the BCR-ABL1
transcript for molecular response monitoring in chronic myeloid leukemia (CML) patients …

The introduction of imatinib in 2000 opened the era of tyrosine kinase inhibitors (TKIs) for
CML therapy and has revolutionized the life expectancy of CML patients, which is now quite …

In recent years, the digital polymerase chain reaction has received increasing interest as it
has emerged as a tool to provide more sensitive and accurate detection of minimal residual …

The effective and sensitive monitoring of Minimal Residual Disease or Measurable Residual
Disease (MRD) is a very important aspect in the management of patients affected by …